Free Trial

Acumen Pharmaceuticals (ABOS) SEC Filings & 10K Form

Acumen Pharmaceuticals logo
$1.40 +0.02 (+1.09%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$1.40 0.00 (0.00%)
As of 02/21/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Acumen Pharmaceuticals SEC Filings

DateFilerForm TypeView
01/23/2025
8:19 PM
Acumen Pharmaceuticals (Issuer)
Zuga Matt (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:14 PM
Acumen Pharmaceuticals (Issuer)
Barton Russell (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:16 PM
Acumen Pharmaceuticals (Issuer)
Meisner Derek M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:18 PM
Acumen Pharmaceuticals (Issuer)
OConnell Daniel Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
4:06 PM
Acumen Pharmaceuticals (Issuer)
Siemers Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2025
3:17 PM
Acumen Pharmaceuticals (Subject)
Zuga Matt (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:31 PM
Acumen Pharmaceuticals (Subject)
Siemers Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:32 PM
Acumen Pharmaceuticals (Subject)
Meisner Derek M (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:24 PM
Acumen Pharmaceuticals (Subject)
OConnell Daniel Joseph (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2025
3:25 PM
Acumen Pharmaceuticals (Subject)
Zuga Matt (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/07/2025
6:57 PM
Acumen Pharmaceuticals (Issuer)
Meisner Derek M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
7:00 PM
Acumen Pharmaceuticals (Issuer)
Doherty James J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
7:02 PM
Acumen Pharmaceuticals (Issuer)
Schacterle Amy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
7:09 PM
Acumen Pharmaceuticals (Issuer)
OConnell Daniel Joseph (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
6:48 PM
Acumen Pharmaceuticals (Issuer)
Siemers Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
6:53 PM
Acumen Pharmaceuticals (Issuer)
Zuga Matt (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2025
6:55 PM
Acumen Pharmaceuticals (Issuer)
Barton Russell (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/03/2025
5:16 PM
Acumen Pharmaceuticals (Subject)
Meisner Derek M (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
4:54 PM
Acumen Pharmaceuticals (Subject)
Zuga Matt (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
4:59 PM
Acumen Pharmaceuticals (Subject)
Barton Russell (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/03/2025
5:04 PM
Acumen Pharmaceuticals (Subject)
Siemers Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/06/2024
4:24 PM
Acumen Pharmaceuticals (Issuer)
Schacterle Amy (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
11/06/2024
4:27 PM
Acumen Pharmaceuticals (Issuer)
Schacterle Amy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:42 PM
Acumen Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/13/2024
6:48 AM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2024
4:26 PM
Acumen Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:40 PM
Acumen Pharmaceuticals (Issuer)
Drapkin Kimberlee C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:41 PM
Acumen Pharmaceuticals (Issuer)
Fountain Nathan B (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:46 PM
Acumen Pharmaceuticals (Issuer)
Porter Derrell (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:49 PM
Acumen Pharmaceuticals (Issuer)
Stalfort John A III (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2024
3:51 PM
Acumen Pharmaceuticals (Issuer)
Stoppel Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
3:36 PM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2024
3:47 PM
Acumen Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/14/2024
6:35 AM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2024
11:15 PM
Acumen Pharmaceuticals (Filer)
Form EFFECT
04/22/2024
3:33 PM
Acumen Pharmaceuticals (Filer)
Form ARS
04/22/2024
3:30 PM
Acumen Pharmaceuticals (Filer)
Form DEF 14A
04/22/2024
3:31 PM
Acumen Pharmaceuticals (Filer)
Form DEFA14A
03/27/2024
3:34 PM
Acumen Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
03/27/2024
3:34 PM
Acumen Pharmaceuticals (Filer)
Form S-3
Registration statement under Securities Act of 1933  
03/26/2024
8:16 AM
Acumen Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
Collect $7k per month from Tesla’s SECRET dividend (Ad)

There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?

Click here to uncover Tesla's hidden income secret.
03/26/2024
6:42 AM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/19/2024
7:05 AM
Acumen Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ABOS) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners